Empirical antibiotic therapy received (N = 477).

BackgroundDifficult-to-treat resistant (DTR) Pseudomonas aeruginosa infections have emerged as a significant global public health threat, characterized by limited treatment options and a heightened mortality risk. This study aimed to assess the appropriateness of initial antibiotic therapy, estimate 30-day all-cause mortality, and determine the impact of DTR P. aeruginosa infections on mortality.MethodsA retrospective, multicenter study was conducted at four teaching hospitals in Beirut, Lebanon, between January 2021 and December 2023. The primary outcome was 30-day all-cause mortality. Kaplan-Meier survival analysis was used to assess time-to-mortality, and the log-rank test was applied to compare survival outcomes relative to DTR infections and the appropriateness of initial antibiotic therapy. Multivariable logistic regression was performed to identify predictors of mortality.ResultsOut of 2,639 screened cases, 477 patients met the inclusion criteria. Respiratory tract infections accounted for 38.8% of cases. Carbapenem-resistant P. aeruginosa (CRPA) comprised nearly one-third of isolates, and 15.3% were categorized as DTR. The most common empirical antibiotics were piperacillin-tazobactam (33.9%) and meropenem (24.5%). Inappropriate initial antibiotic therapy was observed in 43.8% of cases, with 33.8% of patients receiving antibiotics to which the pathogen was resistant. DTR infections were significantly more likely to be associated with inappropriate therapy (odds ratio [OR] = 4.21, 95% CI = 2.43–7.32, P P. aeruginosa infection (adjusted odds ratio [AOR] = 2.48, 95% CI = 1.32–4.63, P ConclusionDTR P. aeruginosa infections and inappropriate initial antibiotic therapy are associated with increased mortality risk in hospitalized patients.